Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Accumulated Expenses (2016 - 2021)

GT Biopharma (GTBP) has disclosed Accumulated Expenses for 11 consecutive years, with $4.8 million as the latest value for Q4 2020.

  • On a quarterly basis, Accumulated Expenses rose 136.57% to $4.8 million in Q4 2020 year-over-year; TTM through Dec 2020 was $4.8 million, a 136.57% increase, with the full-year FY2020 number at $4.8 million, up 136.57% from a year prior.
  • Accumulated Expenses was $4.8 million for Q4 2020 at GT Biopharma, up from $4.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $4.8 million in Q4 2020 to a low of $57000.0 in Q3 2017.
  • A 5-year average of $1.7 million and a median of $1.5 million in 2019 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: tumbled 98.75% in 2016, then surged 1397.19% in 2019.
  • GT Biopharma's Accumulated Expenses stood at $417000.0 in 2016, then crashed by 75.54% to $102000.0 in 2017, then skyrocketed by 237.25% to $344000.0 in 2018, then skyrocketed by 489.83% to $2.0 million in 2019, then soared by 136.57% to $4.8 million in 2020.
  • Per Business Quant, the three most recent readings for GTBP's Accumulated Expenses are $4.8 million (Q4 2020), $4.2 million (Q3 2020), and $3.3 million (Q2 2020).